Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates


Posted on 2 February 2021 | Posted in Alirocumab
Trial Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry (PERI-DYS) Identifier: NCT03110432

Aim Registry study
Study design Prospective observational registry. Patients will receive either standard lipid lowering therapy (statins, ezetimibe, nicotinic acid, fibrates, cholestagel, omega-3 fatty acids and any combinations of these agents), or a PCSK9 inhibitor. The duration of the study is 3 years.
Patients 2000 patients with dyslipidemia with very high cardiovascular risk who principally meet the Gemeinsamer Bundesausschuss (G-BA) stipulations for PCSK9 use, and are treated by office-based cardiologists or in lipid ambulances.
Primary outcome LDL cholesterol goal achievement < 70 mg/dl at 3 years
Key results Ongoing
Author conclusion  

Related content